Lu Yingyu, Chen Jianqiang, He Xueling, Xu Shuoxi, Chen Yong-Er, Gao Jie, Hou Shaozhen
School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Front Pharmacol. 2021 Sep 28;12:714065. doi: 10.3389/fphar.2021.714065. eCollection 2021.
With the increasing incidence of ulcerative colitis (UC) in China, Chinese medicinal herbs or relatively active compounds are widely applied in treating UC. These medicines may be combined with other therapeutic agents such as vitamin D. Nevertheless, the efficacy of these combinations for UC is unclear. Geniposide is an active component in many Chinese herbal medicines. It could ameliorate dextran sulfate sodium (DSS)-induced colitis in mice. This study was designed to determine the efficacy and mechanism of the single use and combination of geniposide and vitamin D on a mouse model of acute colitis. Data showed that a single administration of geniposide (2 mg/kg) or vitamin D (4 IU/day) could significantly improve the symptoms of UC and relieve colon damage. Geniposide and vitamin D could significantly decrease the levels of TNF-α and IL-6 in serum and colon, and increase the level of IL-10 in the colon. However, the combined treatment of geniposide (2 mg/kg) and vitamin D (4 IU/day) exerted less beneficial effects on UC in mice, indicating by less improvement of UC symptoms, colon damage, and inflammatory infiltration. The combination only downregulated the level of TNF-α in serum and IL-6 in the colon. Our data further demonstrated that geniposide could inhibit the activation of p38 MAPK and then restrict the vitamin D receptor signaling stimulated by vitamin D. These results implied that the combination of geniposide and vitamin D might not be an ideal combined treatment for acute colitis, and the combination of vitamin D supplementary and geniposide (or herbal medicines rich in geniposide) need more evaluation before being applied to treat UC in clinic.
随着中国溃疡性结肠炎（UC）发病率的上升，中草药或相对活性化合物被广泛应用于治疗UC。这些药物可能与其他治疗剂如维生素D联合使用。然而，这些联合用药对UC的疗效尚不清楚。栀子苷是许多中草药中的活性成分。它可以改善葡聚糖硫酸钠（DSS）诱导的小鼠结肠炎。本研究旨在确定栀子苷和维生素D单用及联用对急性结肠炎小鼠模型的疗效及机制。数据显示，单次给予栀子苷（2mg/kg）或维生素D（4IU/天）可显著改善UC症状并减轻结肠损伤。栀子苷和维生素D可显著降低血清和结肠中TNF-α和IL-6的水平，并增加结肠中IL-10的水平。然而，栀子苷（2mg/kg）和维生素D（4IU/天）联合治疗对小鼠UC的有益作用较小，表现为UC症状、结肠损伤和炎症浸润改善较少。联合用药仅下调了血清中TNF-α和结肠中IL-6的水平。我们的数据进一步表明，栀子苷可抑制p38 MAPK的激活，进而限制维生素D刺激的维生素D受体信号传导。这些结果表明，栀子苷和维生素D联合可能不是急性结肠炎的理想联合治疗方案，在临床应用于治疗UC之前，维生素D补充剂与栀子苷（或富含栀子苷的草药）的联合需要更多评估。
